These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25576445)

  • 21. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging.
    Nesteruk M; Nesteruk T; Styczyńska M; Barczak A; Mandecka M; Walecki J; Barcikowska-Kotowicz M
    Neurol Neurochir Pol; 2015; 49(6):349-53. PubMed ID: 26652867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease.
    Julayanont P; Brousseau M; Chertkow H; Phillips N; Nasreddine ZS
    J Am Geriatr Soc; 2014 Apr; 62(4):679-84. PubMed ID: 24635004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
    Lewczuk P; Popp J; Lelental N; Kölsch H; Maier W; Kornhuber J; Jessen F
    J Alzheimers Dis; 2012; 28(1):119-25. PubMed ID: 21971403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
    Oh J; Lee HJ; Song JH; Park SI; Kim H
    Exp Gerontol; 2014 Dec; 60():87-91. PubMed ID: 25304332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
    Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
    Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid.
    Monge Argilés JA; Blanco Cantó MA; Leiva Salinas C; Flors L; Muñoz Ruiz C; Sánchez Payá J; Gasparini Berenguer R; Leiva Santana C
    Neurologia; 2014 Sep; 29(7):397-401. PubMed ID: 23969296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
    Verhey FR; Visser PJ
    Ned Tijdschr Geneeskd; 2013; 157(11):A5596. PubMed ID: 23484512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
    Bocchetta M; Galluzzi S; Kehoe PG; Aguera E; Bernabei R; Bullock R; Ceccaldi M; Dartigues JF; de Mendonça A; Didic M; Eriksdotter M; Félician O; Frölich L; Gertz HJ; Hallikainen M; Hasselbalch SG; Hausner L; Heuser I; Jessen F; Jones RW; Kurz A; Lawlor B; Lleo A; Martinez-Lage P; Mecocci P; Mehrabian S; Monsch A; Nobili F; Nordberg A; Rikkert MO; Orgogozo JM; Pasquier F; Peters O; Salmon E; Sánchez-Castellano C; Santana I; Sarazin M; Traykov L; Tsolaki M; Visser PJ; Wallin ÅK; Wilcock G; Wilkinson D; Wolf H; Yener G; Zekry D; Frisoni GB
    Alzheimers Dement; 2015 Feb; 11(2):195-206.e1. PubMed ID: 25150733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment.
    Martínez-Torteya A; Treviño V; Tamez-Peña JG
    Biomed Res Int; 2015; 2015():961314. PubMed ID: 26106620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease.
    Teipel SJ; Sabri O; Grothe M; Barthel H; Prvulovic D; Buerger K; Bokde AL; Ewers M; Hoffmann W; Hampel H
    J Alzheimers Dis; 2013; 33 Suppl 1():S329-47. PubMed ID: 22735677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues.
    Porteri C; Albanese E; Scerri C; Carrillo MC; Snyder HM; Martensson B; Baker M; Giacobini E; Boccardi M; Winblad B; Frisoni GB; Hurst S;
    Neurobiol Aging; 2017 Apr; 52():132-140. PubMed ID: 28317644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association.
    Versijpt J; Tant M; Beyer I; Bier JC; Cras P; De Deyn PP; De Wit P; Deryck O; Hanseeuw B; Lambert M; Lemper JC; Mormont E; Petrovic M; Picard G; Salmon E; Segers K; Sieben A; Thiery E; Tournoy J; Vandewoude M; Ventura M; Verschraegen J; Engelborghs S; Goffin T; Deneyer M; Ivanoiu A
    Acta Neurol Belg; 2017 Dec; 117(4):811-819. PubMed ID: 28983881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.